Immunai, a deep-learning startup, has raised $60 million in Series A funding from the Schusterman Foundation and other investors. The startup uses AI to study how immune systems respond to disease, signaling potential therapeutic insights for pharmaceutical companies. In addition to the Schusterman Foundation, Immunai’s backers include Wiggers Ventures and venture capitalists from the U.S., Israel, and Europe. This latest round of financing provides Immunai with the capital they need to expand their research capabilities while also scaling their core technology platform.
What is immunai?
The human body is able to recognize and fight infection thanks to the immune system. The immune system is made up of a network of cells, tissues, and organs that work together to protect the body from foreign invaders. The thymus, bone marrow, lymph nodes, spleen, and tonsils are all part of the immune system.
Immunai is a startup that is working on artificial intelligence (AI) for immunology. The company was founded in 2016 by CEO Jörn Schuster and CTO Alex Wiggers. Schuster is a serial entrepreneur who has founded several companies, including ecommerce platform Jimdo and digital marketing agency 9flats. Wiggers is a computational biologist who did his PhD at the Max Planck Institute for Molecular Genetics.
The company’s goal is to “empower every scientist with AI” and “to make immunology easy to understand”. Immunai wants to use AI to help researchers find new cures for diseases faster. The company has raised $4 million in seed funding from investors such as Schusterman Foundation, Wiggers Ventures, and VentureBeat.
What does the company do?
The company focuses on providing a better understanding of the human immune system and its response to various diseases. The company has developed a technology that can be used to create a personalized medicine approach for each individual.
How much money has the company raised?
According to Crunchbase, immunai has raised a total of $10.5M in funding over 2 rounds. Their latest funding was raised on Jun 5, 2019 from a Series A round.
immunai has been backed by investors including Schusterman Foundation, Wiggers VentureBeat, and others.
Who are the company’s investors?
The company’s investors are the Schusterman Foundation, Wiggers Venturebeat, and the Immunai M Series.
The Schusterman Foundation is a philanthropic organization that funds a variety of initiatives in the Jewish community and Israel.
Wiggers Venturebeat is a venture capital firm that invests in early-stage companies.
The Immunai M Series is an investment vehicle for immunotherapy companies.
What is the company’s valuation?
The company’s valuation is $1.2 billion.
How does the company compare to its competitors?
The startup immunai, which is backed by the Schusterman Foundation and Wiggers, has developed a platform that it says can map the entire human immune system. The company plans to use the platform to develop new drugs and vaccines.
In terms of competition, immunai faces off against two other startups working on similar technology, including Immudex and Immunocore. Both of these companies are well-funded and have partnerships with major pharmaceutical companies. However, immunai has a few key advantages that could help it succeed in the marketplace.
First, immunai has developed a unique technology that allows it to map the entire human immune system. This is a significant advantage over its competitors, who are only able to map portions of the immune system.
Second, immunai has assembled an impressive team of scientists and executives. This includes co-founder and CEO Daniel Davis, who previously worked at Google; chief scientific officer Michael Eisenberg, who is a leading expert in immunology; and president David Mitchell, who is a veteran biotech executive.
Third, immunai has already secured partnerships with several major pharmaceutical companies, including Pfizer and Merck. These partnerships give the company access to important resources and expertise that will be critical to its success.
Fourth, immunai is based in Israel, which is home to some of the world’s leading life sciences companies. This gives the company access to a deep pool of talent and resources.
fifth key
What are the challenges that the company faces?
The company faces several challenges, including the need to continue to develop its technology and expand its customer base. Additionally, the company must maintain a high level of customer satisfaction and continue to grow its revenue.
Conclusion
Immunai’s 60m series of investments has improved the prospects of many companies, such as Schusterman Foundation and Wiggers Venturebeat. These investments have helped these businesses to grow and expand their reach, while providing a valuable boost to the wider economy. Immunai’s 60m Series is an important step forward in creating innovative solutions that can help build a better future for all of us. We look forward to seeing what else they come up with next!
